EF Hutton Initiates Coverage On Werewolf Therapeutics with Buy Rating, Announces Price Target of $8.3
EF Hutton analyst Michael King initiates coverage on Werewolf Therapeutics (NASDAQ:HOWL) with a Buy rating and announces Price Target of $8.3.